<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252027</url>
  </required_header>
  <id_info>
    <org_study_id>S62242</org_study_id>
    <nct_id>NCT04252027</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring of Fluconazole in Critically Ill Patients</brief_title>
  <official_title>Therapeutic Drug Monitoring of Fluconazole in Critically Ill Patients: a Longitudinal Follow-up of Trough Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective study will research the exposure and its variability to fluconazole after
      longitudinal administration in critically ill patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, monocenter pharmacokinetic study will be carried out in critically ill
      patients, admitted at the University Hospitals Leuven, receiving multiple dose treatment with
      fluconazole.

      The exposure to fluconazole in the ICU cohort over multiple days of treatment will be
      documented. Moreover, variability and the correlating covariates that can influence the
      fluconazole concentration, will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to fluconazole (trough levels)</measure>
    <time_frame>On the day of sampling</time_frame>
    <description>To document the trough levels (Cmin) of fluconazole in an ICU cohort over multiple days of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exposure to fluconazole (trough levels)</measure>
    <time_frame>June 2020</time_frame>
    <description>Determine if the Cmin target levels are attained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variability in fluconazole trough levels</measure>
    <time_frame>June 2020</time_frame>
    <description>To determine the intra-and intersubject variability of the fluconazole trough levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influencing covariates</measure>
    <time_frame>June 2020</time_frame>
    <description>Determine possible covariates that might explain the fluconazole variability</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Critically Ill Patients</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sample collection</intervention_name>
    <description>Plasma and urine sample collection</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years

          -  Treatment with fluconazole

          -  Admitted to an ICU ward

        Exclusion Criteria:

          -  &lt; 18 years

          -  DNR 2 or 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabel Spriet, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabel Spriet, PharmD, PhD</last_name>
    <phone>+32 16 34 30 80</phone>
    <email>isabel.spriet@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruth Van Daele, PharmD</last_name>
    <phone>+32 16 34 30 80</phone>
    <email>ruth.vandaele@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Spriet, PharmD, PhD</last_name>
      <phone>+32 16 34 30 80</phone>
      <email>isabel.spriet@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Van Daele, PharmD</last_name>
      <phone>+32 16 34 30 80</phone>
      <email>ruth.vandaele@uzleuven.be</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 28, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Fluconazole</keyword>
  <keyword>Variability</keyword>
  <keyword>Target attainment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

